Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03712137 · ClinicalTrials.gov registry record · Phase 3

Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition

A Phase 3 study, sponsored by Allergan.

Completed
Registry status
Phase 3
Development phase
206
Enrollment target

NCT03712137: Completed Phase 3 study, sponsored by Allergan.

NCT03712137 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 206 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03712137, a Phase 3 study, has completed, sponsored by Allergan.

COMPLETED
Registry status
Phase 3
Development phase
206 participants
Enrollment target

Study Summary

This study will evaluate the safety and effectiveness of JUVÉDERM VOLUX™ XC injectable gel for restoring jawline definition

Primary Outcome

The ALJDS is an Investigator assessment of loss of jawline definition measured by a 5-point scale (0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Extreme)

Interventions

  • OTHER No-treatment control
  • DEVICE VOLUX XC

Trial Details

FieldValue
Enrollment Target 206 participants
Start Date 2018-11-12
Est. Completion 2021-01-26
Phase Phase 3
Allergan

314 total trials

What the finished NCT03712137 record still lists

NCT03712137 is an interventional study that assigns participants to a tested intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower).

The record links to 0 conditions, and to 2 interventions - of which No-treatment control is the first listed.

NCT03712137 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03712137 about?

NCT03712137 is a clinical study titled "Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition". This study will evaluate the safety and effectiveness of JUVÉDERM VOLUX™ XC injectable gel for restoring jawline definition

What is the current status of trial NCT03712137?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 206 participants. The study started on 2018-11-12. Estimated completion is 2021-01-26.

What interventions are being tested in trial NCT03712137?

The interventions under investigation include: No-treatment control (OTHER), VOLUX XC (DEVICE).

Who is sponsoring clinical trial NCT03712137?

This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03712137's enrollment target sits among peer trials

206 1347th of 2000 higher than 651 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03373968 · 206 participants · Phase 2

    Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study

  • NCT03550391 · 206 participants · Phase 3

    Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

  • NCT04757116 · 206 participants · NA

    Post-Market Study to Assess iTind Safety in Comparison to UroLift

  • NCT05675865 · 206 participants · NA

    Cryoablation for Monomorphic Ventricular Tachycardia

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03712137, the US trial registry maintained by the National Library of Medicine. NCT03712137 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.